Nir Nimrodi Joins Rapid Medical’s Board of Directors

Rapid Medical has appointed Nir Nimrodi to its Board of Directors. He has more than three decades of global leadership in the biotechnology and life sciences industries, with extensive experience in strategic growth, commercialization, and M&A for high-impact healthcare companies.

“I am honored to join Rapid Medical’s Board and contribute to the company’s mission of advancing neurovascular interventions,” Nimrodi said. “Rapid’s portfolio is transforming patient care in stroke and aneurysm treatment, and I look forward to collaborating with the team to support its next stage of growth.”

With a career spanning executive roles at companies including Accellix, Intrexon, Life Technologies, and Proneuron Biotechnologies, Nimrodi has consistently driven innovation and scale across diverse healthcare sectors. He currently serves as an operating partner at ARCHIMED, a healthcare-focused investment firm, and sits on multiple boards in the biotech and life science fields.

“We are thrilled to welcome Nir to the Rapid Medical Board,” Rapid Medical Board Chair Shimon Eckhouse, Ph.D., stated. “His proven ability to guide healthcare companies through expansion and value creation will be invaluable as we accelerate the adoption of our neurovascular technologies worldwide.”

Rapid Medical expands the possibilities in neurovascular treatment by pioneering advanced interventional devices that treat ischemic and hemorrhagic stroke. Using proprietary manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the anatomy and tailor the approach to every patient for better procedural outcomes. TIGERTRIEVER™ 13, 17, and 21, COMANECI, COLUMBUS™/ DRIVEWIRE 14, and DRIVEWIRE 24 are CE marked and cleared by the U.S. Food and Drug Administration cleared. TIGERTRIEVER XL and 25 are also CE marked.